Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, Heinz Gisslinger, Wiesław Wiktor-Jȩdrzejczak, Mamia Zodelava, Katja Weisel, Nicola Cascavilla, Genadi Iosava, Michele Cavo, Janusz Kloczko, Joan Bladé, Meral Beksac, Ivan Spicka, Torben Plesner, Joergen Radke, Christian LangerDina Ben Yehuda, Alessandro Corso, Lindsay Herbein, Zhinuan Yu, Jay Mei, Christian Jacques, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone- lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. METHODS: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. RESULTS: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P

Original languageEnglish
Pages (from-to)1759-1769
Number of pages11
JournalNew England Journal of Medicine
Volume366
Issue number19
DOIs
Publication statusPublished - May 10 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Continuous lenalidomide treatment for newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jȩdrzejczak, W., Zodelava, M., Weisel, K., Cascavilla, N., Iosava, G., Cavo, M., Kloczko, J., Bladé, J., Beksac, M., Spicka, I., Plesner, T., Radke, J., ... Dimopoulos, M. A. (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine, 366(19), 1759-1769. https://doi.org/10.1056/NEJMoa1112704